). Thus, it has been hypothesized that ET-1 might play a pathophysiological role in congestive heart failure. 17 In favor of this idea are findings from Kiowski et al 18 showing that treatment of CHF patients with the nonselective ET A /ET B receptor antagonist bosentan markedly improved hemodynamic parameters and increased cardiac index. Moreover, Sakai et al 19 recently demonstrated that in a rat model of myocardial infarction, long-term treatment with the selective ET A receptor antagonist BQ-123 improved the survival rate of these rats.
The aim of the present study was to gain further insight into the properties of human cardiac ET receptors and their possible alterations in CHF patients. We therefore assessed ET receptor density and subtype distribution and the effects of ET-1 on IP formation and adenylyl cyclase activity in right atria and left ventricles from CHF patients compared with NFH.
Methods

Study Patients
Myocardial tissue was obtained from the Essen, Germany, cardiac transplant program from 1989 through 1993. Atrial and ventricular human myocardium was obtained at the time of explantation from 15 heart transplant recipients. Six hearts were removed from patients with end-stage DCM and 9 from patients with end-stage ICM. All patients had given written informed consent before surgical procedures were performed. They were classified in NYHA functional class III to IV and IV with an ejection fraction of 21.3Ϯ1.6%, left ventricular end-diastolic pressure of 21.1Ϯ3.7 mm Hg, and a cardiac index of 2.2Ϯ0.2 L ⅐ min Ϫ1 ⅐ m Ϫ2 . Tissues samples taken at the time of explantation were either immediately frozen in liquid nitrogen and stored at Ϫ80°C until use or immediately used for experiments. Ten patients were treated with digoxin, 11 with ACE inhibitors, 10 with diuretics, 8 with nitrates, and 6 with calcium antagonists; in addition, they were treated occasionally with lipid-lowering drugs (nϭ3), antiarrhythmics (nϭ4), and aspirin (nϭ3). Patients who had received catecholamines or ␤-adrenoceptor antagonists were withdrawn from the study. General anesthesia was performed with flunitrazepam, fentanyl, and pancuronium bromide with enflurane. Cardiac surgery was performed on cardiopulmonary bypass. The cardioplegic solution used was a Bretschneider-HTK solution.
Control Group
Right atrial appendages were obtained from 18 patients (12 male, 6 female; mean age, 59.8Ϯ2.5 years) undergoing coronary artery bypass grafting who were in NYHA functional class I. No patient suffered from acute myocardial failure or had been treated with catecholamines or ␤-adrenoceptor antagonists for at least 3 weeks before the operation. In addition, left ventricular myocardial tissues from 6 nonfailing control hearts were obtained from organ donors whose hearts could not be used for transplantation because of the lack of a suitable recipient. These patients (4 men aged 23, 33, 43, and 46 years and 2 women aged 29 and 35 years) died from injury to the brain. Patient histories revealed no evidence for heart disease. This study was approved by the ethical committee of the University of Essen.
Radioligand Binding Studies
Tissues were minced with scissors and homogenized in 10 vol of ice-cold 50 mmol/L Tris-HCl buffer, pH 7.4, containing 1 mmol/L EGTA and 10 g/mL aprotinin with an Ultra Turrax (Janke & Kunkel) for 10 seconds at full speed and twice for 20 seconds at half-maximal speed in 1-minute intervals. The homogenate was diluted to 20 mL with homogenization buffer and centrifuged at 700g for 15 minutes. The supernatant was passed through four layers of cheesecloth and centrifuged at 50 000g for 30 minutes. The resulting pellets were washed once by resuspension and recentrifugation and finally resuspended in incubation buffer (50 mmol/L Tris-HCl, pH 7.4, containing 10 mmol/L MgCl 2 , 0.1% BSA, and 1 mg/mL soybean trypsin inhibitor) to yield a protein concentration of 35 to 50 g/mL. Protein content was determined by the method of Bradford 20 using bovine IgG as a standard. Membranes (Ϸ15 g of protein) were incubated with 15 different concentrations of ET-1 ranging from 10 Ϫ13 to 10 Ϫ6 mol/L andϷ10 000 cpm of [ 125 I]ET-1 in siliconized polypropylene tubes in a total volume of 1 mL. 21 Tubes were incubated for 60 minutes at 37°C in a shaking water bath. Bound ligand was separated by vacuum filtration over Whatman GF/C filters coated with 4% BSA followed by washing with 2ϫ 10 mL of incubation buffer. The radioactivity of the wet filters was determined in a ␥-counter (Cobra Autogamma, Packard) at an efficiency rate of 80%. Nonspecific binding was defined as binding not displaced by 1 mol/L bosentan. 22 To assess the relative amount of ET A and ET B receptors, membranes were incubated with Ϸ10 000 cpm of [
125 I]ET-1 and 13 concentrations (ranging from 10 Ϫ11 to 10 Ϫ5 mol/L) of the selective ET A receptor antagonist BQ-123, 23 and specific binding was determined as described above. Details have been described previously. 21 ET-1 and BQ-123 competition curves were analyzed by the iterative curvefitting program InPlot (GraphPad software). Statistical analysis was performed using the F test to measure the goodness of fit of the competition curves for either one or two sites. From the ET-1 competition curves, B max and K d values were calculated as recently described.
21
Adenylyl Cyclase Determination
Adenylyl cyclase activity was assessed as previously described in detail. 24 Membranes ( 25 Column recovery was usually 70% to 80%. Western Blotting G q/11 protein ␣-subunits were quantified by immunoblotting as previously described in detail. 24, 26 Briefly, ␣-subunits of G q/11 were detected with the use of the antiserum QL at a 1:600 dilution, followed by quantification of the blots with [
IP Determination
125 I]protein A solution.
Statistical Evaluation
Data are presented as meanϮSEM of n experiments. Experimental data were analyzed by computer-supported iterative nonlinear regression analysis using the InPlot program (GraphPAD Software). Data from ET-1-induced IP formation and carbachol-and ET-1-induced adenylyl cyclase inhibition were fitted to sigmoid curves. In these calculations, the bottom of the curves was fixed at 0% stimulation or inhibition, respectively; stimulation of IP formation induced by 1 mol/L ET-1 was taken as maximal stimulation and inhibition of adenylyl cyclase by 1 mol/L ET-1 and 100 mol/L carbachol as maximal inhibition; and the Hill slopes were kept variable. From these curves, EC 50 values were obtained that were not considerably different (maximal difference was a factor of two) from those calculated with a
Selected Abbreviations and Acronyms
IP ϭ inositol phosphate IP 3 ϭ inositol trisphosphate NFH ϭ nonfailing human hearts NYHA ϭ New York Heart Association PLC ϭ phospholipase C sf ϭ sarafotoxin
Hill slope fixed at 1.0 and/or with a nonfixed maximal stimulation and inhibition, respectively. BQ-123 affinity (K i ) for inhibition of ET-1-induced adenylyl cyclase inhibition was calculated according to the Cheng and Prusoff Statistical significance of differences was analyzed by unpaired two-tailed Student's t test or, if appropriate, by repeated measures ANOVA followed by the t test using Bonferroni corrections for multiple comparisons. A value of PϽ.05 was considered to be significant. All statistical calculations were performed with the Instat program (GraphPAD Software).
Chemicals
ET-1, ET-3, sf6b and sf6c, and BQ-123 were purchased from Saxon Biochemicals; (Ϯ)-propranolol hydrochloride, (Ϫ)-isoprenaline bitartrate, forskolin, carbachol chloride, aprotinin, and soybean trypsin inhibitor from Sigma Chemical Co; 
Results
IP Formation
In right atrial slices from NFH, ET-1 (10
3 H]IP formation in a concentration-dependent manner; increases at 10 Ϫ6 mol/L were Ϸ90% above basal levels (Fig 1) . Under these experimental conditions, the EC 50 value for ET-1 was 4.4Ϯ1.1 nmol/L (Table 1) 
Adenylyl Cyclase Response
In right atrial and left ventricular membranes of CHF hearts, adenylyl cyclase activation by GTP and isoprenaline was significantly reduced whereas that of NaF was unchanged compared with NFH. Forskolin stimulation of adenylyl cyclase showed a tendency to decline, but this did not reach statistical significance (Fig 4) . ET-1 (10 Ϫ11 to 10 Ϫ6 mol/L) inhibited 10 mol/L isoprenaline-and 10 mol/L forskolin-stimulated adenylyl cyclase activity in right atrial membranes in a concentration-dependent manner (in agreement with our recently published data 15 ) but not in left ventricular membranes (Figs 5 and 6 ). The inhibitory effect of 10 Ϫ7 mol/L ET-1 was inhibited by the ET A receptor antagonist BQ-123 in a concentration-dependent manner; the K i value for BQ-123 was 3.3Ϯ1.1 nmol/L (nϭ3; data not shown). The muscarinic receptor agonist carbachol (10 Ϫ8 to 10 Ϫ4 mol/L), on the other hand, inhibited isoprenaline-and forskolin-stimulated adenylyl cyclase activity, respectively, in both tissues with a similar potency and efficacy (Figs 5 and 7; Table 2 ).
In right atria from CHF hearts, maximal inhibition of isoprenaline-and forskolin-stimulated adenylyl cyclase by ET-1 was not significantly different from that in NFH (Fig 5); however, concentration-response curves for ET-1 were Ϸ5-fold shifted to the right (Fig 6; Table 2 ). On the other hand, carbachol-induced inhibition of isoprenaline-and forskolinstimulated adenylyl cyclase was nearly identical in right atrial and left ventricular myocardium of CHF hearts and NFH (Figs 5 and 7; Table 2 ). As described for IP formation, no significant differences between ICM and DCM hearts were observed for adenylyl cyclase inhibition.
Endothelin Receptors
In NFH hearts, ET receptor density was 167 
G q/11 Protein
Finally, we studied whether G q/11 , the G protein most likely coupling the ET receptor to the PLC/IP 3 /DAG system, 13 might be altered in left ventricular membranes of CHF hearts. The G q/11 -specific antiserum QL detected a single band with an apparent molecular weight of 42.7 kD. However, no significant difference in the amount of [ 125 I]protein A bound in this band could be detected between NFH and CHF hearts (Fig 8) .
Discussion
In the present study, we have quantified and subclassified ET receptors in the human heart with the use of [
125 I]ET-1 radioligand binding studies. The results show that in both right atrial and left ventricular myocardium of NFH, ET A and ET B receptors coexist, a finding consistent with other studies. 8,11,12,28 -30 Moreover, mRNA for both ET A and ET B receptors has been identified in atrial and ventricular myocardium having a similar distribution. 11 The density of ET receptors, however, appears to be Ϸ1.5-to 2-fold higher in atrial tissue than in ventricular myocardium (present study).
Despite the coexistence of ET A and ET B receptors in the human heart, only ET A receptors appear to be of functional importance. As shown in Fig 2, ET receptor agonists induced IP formation in atrial and ventricular myocardium with an order of potency ET-1 ϾϾϾ ET-3, which is the typical one for an ET A receptor. 10 Moreover, ET-1-induced IP formation in human myocardial slices was nearly completely suppressed by the ET A receptor antagonist BQ-123 in a concentration (1 mol/L) that under these experimental conditions occupies Ϸ99% of ET A receptors but Ͻ5% of ET B receptors. 23 In addition, Meyer et al 7 recently showed in human right atrial preparations that the ET receptor mediating the positive inotropic effect of ET-1 is an ET A receptor. Finally, the growth-promoting effect of ET-1 in rat 14, 31, 32 and feline cardiomyocytes 33 was exclusively mediated by ET A receptor stimulation. We recently demonstrated that in human right atria, ET-1 not only increases IP formation but also inhibits isoprenalineor forskolin-stimulated adenylyl cyclase activity. 15 This effect is also mediated by ET A receptors because it is induced by ET receptor agonists with an order of potency ET-1 ϾϾϾ ET-3 15 and is inhibited by BQ-123 with a K i value (3.3 nmol/L) that is well within its range of affinity for ET A receptors. 23 In ventricular myocardium, however, stimulation of ET A receptors does not inhibit adenylyl cyclase. This is not due to an inability of ventricular receptor stimulation to inhibit adenylyl cyclase, because the muscarinic receptor agonist carbachol inhibited isoprenaline-and forskolin-stimulated adenylyl cyclase activity in atrial and ventricular myocardium with similar potency and efficacy (present study; see References 34 through 36). Taken together, these results show that in human right atria, ET A receptors couple to IP formation and inhibition of adenylyl cyclase, whereas in human left ventricles, they couple only to IP formation.
In CHF patients, plasma ET-1 concentrations are increased. 16 Thus, in CHF, cardiac ET receptors are chronically exposed to high concentrations of ET-1, and it could be expected, therefore, that they might be downregulated and/or desensitized. However, this is obviously not the case. In the present study, ET A receptor density was decreased neither in right atrium nor in left ventricle of CHF patients but rather showed a tendency to increase (cf "Results"); similarly, preliminary data from Pieske et al 8 described increased left ventricular ET A receptors in CHF patients. In addition, ET A receptor-mediated IP formation was not different in atrial and ventricular tissues of CHF patients versus that in NFH. Moreover, the immunodetectable amount of G q/11 was not significantly different between CHF hearts and NFH. Thus, the ET A receptor in CHF patients shows a similar pattern as the ␣ 1 -adrenoceptor, another presumably G q/11 -coupled receptor in the human heart: receptor density is unchanged or slightly increased, and IP formation is unchanged compared with NFH. 34, 36 Moreover, the carbachol-induced IP formation (which very likely also involves G q/11 ) is not different in NFH and CHF hearts. 36 On the other hand, the positive inotropic effect evoked by ␣ 1 -adrenoceptor stimulation in vitro (in isolated right and left ventricular preparations) and in vivo is decreased in CHF hearts. 34, 36 In addition, preliminary results indicate that the ET-1-induced positive inotropic effect in left ventricular preparations of CHF hearts is also decreased. 8 Taken together, it appears that G q/11 -coupled receptors undergo very similar changes in CHF in the human heart: the number is unchanged or increased, G q/11 is unchanged, IP response is unchanged, and the positive inotropic effect is (presumably) decreased. This indicates that human cardiac G q/11 -coupled receptors appear to be uncoupled from the physiological response in end-stage CHF. We do not know why cardiac ET A receptors (and ␣ 1 -adrenoceptors) are not decreased but rather increased in CHF in the face of elevated plasma ET-1 (and norepinephrine) levels and can only speculate as to the reason. One possible mechanism might be related to cross-regulation phenomena, because it has been shown that chronic activation of the adenylyl cyclase/cAMP system (as in CHF) can upregulate mRNA levels for ET A receptors 37 and ␣ 1 -adrenoceptors. 38 Another possibility might be that ET-1 that is generated and secreted locally in the heart is more important for regulation of cardiac ET A receptors than circulating ET-1. It has been proposed that Ang II plays an important role in maintaining local ET-1 concentrations in the heart, presumably via AT 1 receptor stimulation on cardiac fibroblasts. 31, 39 Because cardiac AT 1 receptors are downregulated in CHF (see below), it might be that Ang II fails to induce production of sufficient amounts of local ET-1 to downregulate the cardiac ET A receptor.
In contrast to ␣ 1 -adrenoceptors and ET A receptors, the AT 1 receptor, which also presumably couples via G q/11 in the human heart, is decreased in ventricular myocardium of CHF patients; this has been found on a protein 40, 41 and mRNA level. 42 The reason for this differential regulation of cardiac G q/11 -coupled receptors in CHF patients is not clear. However, the properties of human cardiac AT 1 receptors differ from those of ET A receptors and ␣ 1 -adrenoceptors: whereas norepinephrine and ET-1 cause positive inotropic effects in right atrial and left ventricular preparations of the human heart, several groups have convincingly shown that Ang II exerts positive inotropic effects in right atrial but not in left ventricular preparations of the human heart. 34 This raises the question whether AT 1 receptors are localized on cardiomyocytes or on nonmyocyte cells in human ventricular myocardium; in rat heart, it has been shown that the AT 1 receptor is localized predominantly on nonmyocyte cells (mainly cardiac fibroblasts) and that the AT 1 receptor on these cells plays a critical role in Ang II-mediated effects in neonatal rat cardiomyocytes. 31, 43, 44 In human heart, AT receptors have been not directly identified on cardiomyocytes but have been demonstrated to exist on fibroblasts. 45 A large body of evidence has accumulated that shows that in end-stage CHF, the functional activity of the inhibitory G protein G i is increased. 34 -36,46,47 This is also found in the present study: the GTP response of adenylyl cyclase (concomitant activation of G s and G i ) was decreased whereas that of NaF (activating only G s under these conditions) was unchanged, a typical pattern of adenylyl cyclase activation in severely failing human hearts. 34 -36,46,47 Despite the increase in the functional activity of G i , however, inhibition of isoprenaline-and forskolin-stimulated adenylyl cyclase activity by carbachol and ET-1 was not considerably different in NFH and CHF hearts. These results are in good agreement with data from the literature that show that in CHF, the number of muscarinic receptors is not changed and the negative inotropic effect of carbachol is unaltered. 34 -36 A limitation of our study is that we have used myocardial homogenates that contain not only cardiomyocytes but also a variety of other cell types. However, in the human heart, ET-1 causes IP formation (present study) and positive inotropic effects 3,4,6 -8 via ET A receptor stimulation, and ET receptors mediating increases in contraction have been demonstrated on isolated human ventricular cardiomyocytes. 5 Thus, at least some of the effects described in the present study are representative for ET A receptors on cardiomyocytes. Whether this holds true for ET B receptors and on which cell type they are localized remains to be elucidated.
In conclusion, ET A and ET B receptors coexist in the human heart; however, only ET A receptors appear to be of functional importance. In atrial tissue, ET A receptors couple to IP formation (very likely via G q/11 ) and inhibition of adenylyl cyclase (very likely via G i ), whereas in ventricular myocardium, they only couple to G q/11 . In severely failing human hearts, ET A receptor density, the immunodetectable amount of G q/11 , and ET-induced IP formation is unchanged, a pattern very similar to that found for human cardiac ␣ 1 -adrenoceptors. The fact that ET A receptor-and ␣ 1 -adrenoceptor-mediated IP formation are unchanged in severely failing human hearts might be of pathophysiological importance; it has been suggested 48 that the PLC/IP 3 /DAG pathway, with subsequent activation of protein kinase C, can increase the rate of protein synthesis and hence is involved in the hypertrophic response. Thus, in CHF patients with elevated endogenous norepinephrine and ET-1, long-term stimulation of ET A receptors and ␣ 1 -adrenoceptors might significantly contribute to development of cardiac hypertrophy, as is often seen in CHF patients.
